文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-FDG PET/CT 量化肺结节病活动度:SUVmax 与全肺糖酵解的比较

Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis.
PubMed 文献 · EJNMMI Res · 2019-06-13

本研究回顾性纳入27例因难治性肺结节病开始英夫利西单抗治疗的患者,比较治疗前后SUVmax与全肺糖酵解(TLuG)变化与肺功能变化的相关性及基线代谢指标的预测价值。结果显示两者变化均与肺功能变化相关,基线SUVmax和TLuG均可预测治疗后肺功能改善;鉴于TLuG更耗时,作者推荐使用肺实质SUVmax进行疗效监测。

要点

  • ΔSUVmax与ΔFVC(r=-0.497,p=0.008)和ΔFEV1(r=-0.467,p=0.014)显著相关。
  • ΔTLuG与ΔFVC、ΔFEV1和ΔDLCOc均显著相关,且与ΔSUVmax显著相关(r=0.735,p<0.001)。
  • 基线SUVmax>7.5预测FVC改善5%,>9.2预测DLCOc改善5%;TLuG>4100预测FVC和FEV1改善5%,>4500预测DLCOc改善5%。

核心结论

  • SUVmax与TLuG在判断肺结节病患者对英夫利西单抗治疗反应方面效果相当。
  • 基线SUVmax和TLuG均可预测英夫利西单抗治疗后肺功能变化。
  • 鉴于TLuG更耗时,推荐使用肺实质SUVmax进行肺结节病疗效监测。

研究设计与样本

  • 回顾性队列研究,纳入27例因难治性肺结节病开始英夫利西单抗治疗的患者。
  • 英夫利西单抗每月静脉给药,剂量为5 mg/kg。
  • 在英夫利西单抗治疗前和治疗6个月后进行肺功能检查和18F-FDG PET/CT,测定治疗前后SUVmax和TLuG。

主要发现

  • ΔSUVmax与ΔFVC(r=-0.497,p=0.008)和ΔFEV1(r=-0.467,p=0.014)显著相关。
  • ΔTLuG与ΔFVC(r=-0.430,p=0.025)、ΔFEV1(r=-0.532,p=0.004)和ΔDLCOc(r=-0.423,p=0.039)显著相关。
  • ΔSUVmax与ΔTLuG显著相关(r=0.735,p<0.001)。
  • 基线SUVmax与FVC和DLCOc的变化显著相关;基线TLuG与FEV1和DLCOc的变化显著相关。

关键数值与推荐

  • 基线SUVmax>7.5预测英夫利西单抗治疗后FVC改善5%。
  • 基线SUVmax>9.2预测英夫利西单抗治疗后DLCOc改善5%。
  • 基线TLuG>4100预测英夫利西单抗治疗后FVC和FEV1改善5%。
  • 基线TLuG>4500预测英夫利西单抗治疗后DLCOc改善5%。

临床怎么用

  • 可使用肺实质SUVmax对肺结节病患者英夫利西单抗治疗反应进行监测。
  • 基线SUVmax或TLuG可用于预测英夫利西单抗治疗后肺功能改善程度。
  • TLuG较SUVmax耗时,临床常规疗效监测优先选择SUVmax。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 18F-FDG PET/CT has proven to be a reliable tool for therapy monitoring in sarcoidosis. Previous PET studies investigated the SUVmax as a marker for disease activity. Total lung glycolysis (TLuG) is a new tool, quantifying the glycolysis of the entire lung. Since SUVmax represents the maximum activity in only one pixel, we hypothesize that TLuG is a more accurate marker for active pulmonary disease and predictor of response than SUVmax. METHODS: In this retrospective cohort study, 27 patients started on infliximab for refractory pulmonary sarcoidosis. Patients received infliximab intravenously monthly at a dose of 5 mg/kg. We performed a lung function test and an 18F-FDG PET/CT before initiation of infliximab and after 6 months of treatment. SUVmax and TLuG were determined in the pre- and post-scan. Change in lung function was correlated with the change in SUVmax and TLuG and was correlated to the initial SUVmax and TLuG to evaluate the predictive value of the initial metabolic activity. RESULTS: ΔSUVmax significantly correlated with ΔFVC (r = - 0.497, p = 0.008) and with ΔFEV1 (r = - 0.467, p = 0.014). Furthermore, ΔTLuG significantly correlated with ΔFVC (r = - 0.430, p = 0.025), ΔFEV1 (r = - 0.532, p = 0.004) and ΔDLCOc (r = - 0.423, p = 0.039). Change in SUVmax and TLuG significantly correlated (r = 0.735, p < 0.001). Initial SUVmax significantly correlated with the change in FVC and DLCOc. In addition, initial TLuG significantly correlated with the change in FEV1 and DLCOc. A SUVmax > 7.5 at initiation of infliximab was predictive for 5% response in FVC, whereas SUVmax > 9.2 was predictive for 5% response in DLCOc. In addition, high TLuG > 4100 at initiation of infliximab was predictive for 5% response in FVC and FEV1 and TLuG > 4500 was predictive for response in DLCOc. CONCLUSION: SUVmax and TLuG are equal in determining the response to infliximab in pulmonary sarcoidosis patients. Furthermore, SUVmax and TLuG at initiation of infliximab can predict change in lung function after treatment. Since TLuG is a more time-consuming tool, we recommend to use SUVmax of the lung parenchyma for response monitoring in pulmonary sarcoidosis.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Schimmelpennink MC, Vorselaars ADM, Veltkamp M, et al. Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis. EJNMMI Res. 2019. PMID: 31197630. doi:10.1186/s13550-019-0505-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。